glp-1 and alzheimer's disease drugs failed to slow in two big clinical trials GLP-1 drugs show promise in

Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer

10.1039/d5tb00487j 173 MoovskS.PetkovP.KalikM.MikulajovaA

Over the past year, the clinical and regulatory landscape of GLP-1s has evolved with new indications and approvals expanding their use

For example, alterations in Wnt signalling, alterations in neuronal translation and defects in synaptogenesis or synaptic function during brain development can all affect the formation and activity of neural circuits

They can lower blood pressure, improve lipid profiles, and potentially reduce atherosclerosis progression

Although there is genetic and biochemical evidence that N